Utsav Bali

Interpreting Confidence Intervals Interactive visualization of confidence intervals

#stats Here's a nifty interactive demo of confidence intervals by
Kristoffer Magnusson

rpsychologist.com/d3/ci/

An mRNA Refusal to File

What’s happening with Moderna’s mRNA flu vaccine at the FDA is awful, but unfortunately typical:

Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo Eli Lilly reports strong Q4 2025 with $19.29B revenue, led by tirzepatide sales. Company expects $80-83B revenue in 2026, contrasting with Novo Nordisk's projected decline.

Lilly beats sales forecasts, plots major growth in 2026 in stark contrast to Novo

Mapping the Genetics of Brown Fat - insitro How insitro unlocked population-scale human genetics in a tissue that has resisted measurement for decades – and what it reveals about peripheral approaches to metabolic disease The Furnace We Couldn’...

Mapping the Genetics of Brown Fat www.insitro.com/news/mapping...

From London to Lausanne: how Isomorphic Labs is rewriting drug discovery Google DeepMind spin-off Isomorphic Labs is expanding in Switzerland to achieve its ambitious goal to "solve all diseases" with AI.

www.swissinfo.ch/eng/ai-and-m...

Biopharma Sentiment Index | Q1 2026 After four years of misery, the mood in biopharma strengthened meaningfully going into 2026, with across-the-board gains and early signs of a recovery that might finally stick.

Biopharma Sentiment Index | Q1 2026
The latest BPSI shows signs of a more durable phase in the biopharma recovery, with improvements across every metric.

endpoints.news/biopharma-se...

U.S. government has lost more than 10,000 STEM Ph.D.s since Trump took office A Science analysis reveals how many were fired, retired, or quit across 14 agencies

U.S. government has lost more than 10,000 STEM Ph.D.s since Trump took office | Science | AAAS www.science.org/content/arti...

The Lowdown on Low-Dose Aspirin for Primary Prevention Pivotal Randomized Trials and Guidelines

Eric Topol's post on 'The Lowdown on Low-Dose Aspirin for Primary Prevention'

erictopol.substack.com/p/the-lowdow...

JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view Drugmaker CEOs see online sales channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect a rebound in new stock offerings.

JPM26: Paying cash for obesity drugs, renewed IPO optimism and pharma’s cell therapy view

www.biopharmadive.com/news/jpm26-b...

JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview Speaking on the sidelines of the J.P. Morgan Healthcare Conference, Novo business development executive Tamara Darsow said the company is gunning for obesity and diabetes assets.

JPM26: Deal Hungry Novo Moves With ‘Intention’ To Put Metsera in the Rearview

www.biospace.com/business/dea...

Weight regain after cessation of medication for weight management: systematic review and meta-analysis Objectives To quantify and compare the rate of weight regain after cessation of weight management medications (WMMs) in adults with overweight or obesity. Design Systematic review and meta-analysis. ...

Weight regain after cessation of medication for weight management: systematic review and meta-analysis www.bmj.com/content/392/...

Watch: At #JPM26, former drug regulator Richard Pazdur rings the alarm about politics at FDA
Full session: www.statnews.com/2026/01/13/j...

Biotech on Fire: The Week Leading Into JPM 2026 Hello everyone! The early January vibe is traditionally shaped by JP Morgan Healthcare, but this year’s first week is unusually active, suggesting that maybe, afterall, 2026 could be a genuinely good ...

2026 pre JPM deal landscape is already heating up: www.linkedin.com/pulse/biotec...

Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses Milestone deal secures UK’s medicines access for patients, with a wide range of groundbreaking new treatments to reach NHS front-line quicker.

Landmark UK-US pharmaceuticals deal to safeguard medicines access and drive vital investment for UK patients and businesses

www.gov.uk/government/n...?

AI-Native Biotech Is an Opportunity for UK Leadership and Growth AI-Native Biotech Is an Opportunity for UK Leadership and Growth

AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC institute.global/insights/pub...

AI-Native Biotech Is an Opportunity for UK Leadership and Growth via @InstituteGC

Nxera lays off 15% of staff, pivots pipeline focus in profitability push Nxera Pharma plans to lay off | Nxera Pharma has outlined plans to lay off 15% of its staff and prioritize its pipeline as part of a push to clear its path to profitability.

Nxera lays off 15% of staff, pivots pipeline focus in profitability push www.fiercebiotech.com/biotech/nxer...

Nice perspective on the necessity of creating an ecosystem of innovation in the life sciences...

Bell Labs Wasn't Built in a Day. Or Two Years. omicsomics.blogspot.com/2025/11/bell...

'The Evidence' on the BBC World Service where we discussed weight loss medications, which we recorded at the Wellcome Collection a couple of weeks ago #obesityisnotachoice www.bbc.com/audio/play/p...

Why is AI struggling to discover new drugs? via @ft

Autoimmune Disease, Transformed?

Dozens of clinical trials are underway trying to change the landscape of autoimmune disease therapy:

Is there a renaissance in GPCR drug development? Sitting at the top of many human signalling cascades, G-protein coupled receptors (GPCRs) play crucial roles in mood, sleep, appetite and every heartbeat. Historically challenging to develop, selectiv...

Is there a renaissance in GPCR drug development? www.nature.com/articles/d42...

Another GLP-1 Year

Questions about the GLP-1 agonist class that we might start resolving this year:

Probability isn’t a property of the world but a tool to navigate uncertainty conceived from subjective judgments and assumptions. #AcademicSky #NurseSky #PhilSky

Neuroscience methods - YouTube Nanocourse: Approaches to Study Neural Circuits This course was taught by Anita Autry, Tiago Gonçalves, and Luke Sjulson at Albert Einstein College of Medici...

Neuroscience students asked us to teach a PRACTICAL course on experimental methods, and it is now on YouTube!

Please like and repost to help us get the word out!

www.youtube.com/playlist?lis...

Lecture 1: Signals and data acquisition
Focusing on hardware, digital/analog I/O, synchronization
🧵

Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist Orthogonal murine models demonstrate the bioactivity and neuronal targets of a GLP-1/leptin coagonist in relation to food intake and body weight.

Latest from our group in collaboration with Lotte Bjerre Knudsen and other Novo scientists. They developed a GLP-1/Leptin co-agonist that we put through its paces in a number of mouse models to prove that both parts of the molecule matter. More options on the table!
www.science.org/doi/10.1126/...

Glucagon-like peptide-1 receptor Michael Krashes discusses glucagon-like peptide-1 receptors, their physiological role in glucose metabolism and the mode of action of their agonists that are used to treat obesity and were later shown...

Everyone is talking about #Ozempic #Wegovy which are agonists of the GLP-1 receptor. For more about this receptor and its physiological role, see the quickguide by Michael Krashes in our latest issue

www.cell.com/current-biol...

Atlas Venture 2024 Year in Review - B. Booth via @YouTube

Dose–Response Curves and the Determination of IC50 and EC50 Values | Journal of Medicinal Chemistry

I always like listening to Daphne Koller speak about her views on the intersection of biology and AI. If only we could solve the biological complexity for efficient hypothesis generation - a pipe dream? Here's another one of her podcasts: